Senores slashes branded generics target after promising ₹80-100 cr. No reconciliation given.
India domestic revenue guided to ₹50-60 cr for FY27, down from earlier projections of ₹80-100 cr, as management pivots to profitability without bridging the gap.
What's new
- Q1 FY27 revenue ₹180 cr, up 36% YoY; PAT ₹31 cr, up 56%.
- Approved ANDAs rose 93% to 58; 23 commercialized, 35 more planned for launch.
- India branded generics contributed ₹23 cr in Q1, down 2% YoY.
- EBITDA margin ~30%, up 800-1000 bps YoY.
Themes from the call
Demand
Regulated markets grew 40% YoY, driven by ANDA scale-up and four-channel US commercialization; emerging markets grew 30%.
Margins
Consolidated EBITDA margin hit ~30%, up sharply YoY, though emerging market margin dipped to 14% on seasonality and registration costs.
Capital allocation
IPO proceeds redirected from sterile injectables to oral-solid capacity; small injectable pilot deferred to H2 FY27. FY27 capex guided at ₹100-130 cr.
Guidance watch
- FY27 revenue growth 30-40%, PAT growth 50-60%.
- India domestic revenue ₹50-60 cr (down from earlier ₹80-100 cr).
- 35 ANDAs to be commercialized over next 18-20 months.
- Emerging market EBITDA margin 18-20% for FY27.
- Capex ₹100-130 cr in FY27, ₹60-75 cr minimum next year.
Risk flags
- Branded generics guidance cut not reconciled with prior ₹80-100 cr projections.
- Sterile injectable project downsized and deferred; large greenfield delayed.
- EU revenue potential not quantified despite 100-120 product filings planned.
- Tariff impact unclear, pending US-India trade deal.
Key quotes
-
"On the branded generics side... next year could be another INR80-plus crores is what we are projecting."
— Swapnil Shah, Managing Director, Jan 2026 call -
"Our India domestic business is expected to do 50-60 crores this year. The growth has moderated because of this change in strategy."
— Swapnil Shah, Managing Director, Jul 2026 call
The brief
Senores Pharmaceuticals delivered a strong Q1: revenue of ₹180 cr, up 36% YoY, with EBITDA margin near 30% and PAT up 56%. The regulated-markets engine is humming. Approved ANDAs rose 93% to 58, 23 are already commercialized, and 35 more have launch plans. Emerging markets grew 30% and turned cash-flow positive. The pipeline explosion is real. But the branded-generics story just blew a gasket. In November 2025, management said it planned ₹100 cr in branded generics the next year. In January 2026, that was revised slightly to ₹80-plus cr. Now the same business (called India domestic) is expected to deliver ₹50-60 cr for FY27. The explanation: profitability over volume. No mention of the earlier numbers. No bridge. That cut is nearly 40% from the low end of the prior projection. Markets may reward the margin improvement, but guidance credibility takes a hit. The rest of the story (ANDA pipeline, US commercialization, emerging market scale) remains intact, but investors now have to decide which part of management's word to trust.
Senores' branded generics guidance flip is a dissonance the strong pipeline doesn't resolve.